Evaluate the Safety, Tolerability and Pharmacokinetics of DW5524 in Healthy Adult Volunteers

ConditionHealthy Adult
Trial statusNot yet recruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age19+
SponsorDaewon Pharmaceutical Co., Ltd.

About this trial

This study aimed to evaluate the safety and pharmacokinetic characteristics of DW5524 in healthy adult volunteers.

Eligibility criteria

Qualifiers

Healthy adult volunteers aged 19 years or older at the time of screening

Individuals weighing 50.0 kg or more and having a body mass index (BMI) between 18.0 kg/m2 and 30.0 kg/m2 at the time of screening

Disqualifiers

Those with a current or past medical history of clinically significant liver, kidney, nervous, mental, respiratory, endocrine, blood disease, tumor, genitourinary, cardiovascular, digestive, or musculoskeletal diseases.

Trial design

Treatments tested in this trial

  • DW5524
  • DW5524-A

Treatment groups

48 Participants
are divided into 4 treatment groups